# Zepp Health Corp: Form 20-F for the period ended Dec 31, 2022

- Company: [Zepp Health Corp](/companies/zepp.md) (CIK 1720446)
- Form: 20-F
- Filed: 2023-04-24
- Accepted by EDGAR: Apr 24, 2023, 16:53 ET
- Period: 2022-12-31
- Accession: 0001104659-23-049064
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1720446/000110465923049064/zepp-20221231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1720446/000110465923049064/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2022-01-01 to 2022-12-31 | $600.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2022-01-01 to 2022-12-31 | $484.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2022-01-01 to 2022-12-31 | $116.4m | us-gaap:GrossProfit |
| Research and development | 12 months, 2022-01-01 to 2022-12-31 | $75.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2022-01-01 to 2022-12-31 | −$59.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2022-01-01 to 2022-12-31 | $8.3m | us-gaap:InterestExpense |
| Income tax | 12 months, 2022-01-01 to 2022-12-31 | −$9.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | −$41.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2022-01-01 to 2022-12-31 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2022-01-01 to 2022-12-31 | −$0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2022-01-01 to 2022-12-31 | 246,283,328 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2022-01-01 to 2022-12-31 | −$114.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2022-01-01 to 2022-12-31 | $5.8m | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months, 2022-01-01 to 2022-12-31 | $7.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-12-31 | $128.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $428.9m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $763.7m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $241.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $374.5m | us-gaap:Liabilities |
| Long-term debt | at 2022-12-31 | $99.2m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2022-12-31 | $387.5m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1720446/000110465923049064/zepp-20221231x20f.htm

Filed Apr 24, 2023.
Source: SEC EDGAR, the filing index for accession 0001104659-23-049064. Last ingested by Listed: Nov 5, 2026, 14:06 ET. No prices; not investment advice.